Peijia Medical Limited (FRA:4WO)

Germany flag Germany · Delayed Price · Currency is EUR
0.6950
-0.0200 (-2.80%)
Last updated: Apr 24, 2026, 3:25 PM CET
Market Cap498.98M +25.7%
Revenue (ttm)86.81M +15.8%
Net Income-24.75M
EPS-0.04
Shares Outn/a
PE Ration/a
Forward PE1,543.89
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.7000
Previous Close0.7150
Day's Range0.6950 - 0.7000
52-Week Range0.5600 - 1.0100
Betan/a
RSI59.71
Earnings DateAug 21, 2026

About Peijia Medical

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve s... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2012
Employees 1,022
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4WO

Financial Performance

In 2025, Peijia Medical's revenue was 712.87 million, an increase of 15.82% compared to the previous year's 615.48 million. Losses were -203.29 million, -10.28% less than in 2024.

Financial numbers in CNY Financial Statements

News

Peijia Medical Announces 2025 Annual Results

SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, ...

4 weeks ago - PRNewsWire

DCwire® Micro Guidewire Receives FDA 510(k) Clearance, Marking a Key Milestone in Peijia Medical's Global Expansion

SUZHOU, China, March 18, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, ...

5 weeks ago - PRNewsWire

Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System

HONG KONG, Feb. 9, 2026 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration ap...

2 months ago - PRNewsWire

Peijia Medical Receives NMPA Approval for TaurusTrio Transcatheter Aortic Valve System, Pioneering Treatment for Aortic Regurgitation in China

HONG KONG , Dec. 12, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, anno...

4 months ago - PRNewsWire

Peijia Medical Announces 2025 Interim Results

HONG KONG , Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, annou...

8 months ago - PRNewsWire

Peijia Medical Announces 2024 Annual Results

HONG KONG , March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, anno...

1 year ago - PRNewsWire

Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical

SUZHOU, China , Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, ...

1 year ago - PRNewsWire